AU2003273983A1 - Viral vectors and the use of the same for gene therapy - Google Patents

Viral vectors and the use of the same for gene therapy

Info

Publication number
AU2003273983A1
AU2003273983A1 AU2003273983A AU2003273983A AU2003273983A1 AU 2003273983 A1 AU2003273983 A1 AU 2003273983A1 AU 2003273983 A AU2003273983 A AU 2003273983A AU 2003273983 A AU2003273983 A AU 2003273983A AU 2003273983 A1 AU2003273983 A1 AU 2003273983A1
Authority
AU
Australia
Prior art keywords
same
gene therapy
viral vectors
viral
vectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003273983A
Other languages
English (en)
Other versions
AU2003273983A8 (en
Inventor
Frank Schnieders
Reinhard Wahler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Medical Center Hamburg-Eppendorf
Original Assignee
University Medical Center Hamburg-Eppendorf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Medical Center Hamburg-Eppendorf filed Critical University Medical Center Hamburg-Eppendorf
Publication of AU2003273983A1 publication Critical patent/AU2003273983A1/en
Publication of AU2003273983A8 publication Critical patent/AU2003273983A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003273983A 2002-10-11 2003-10-10 Viral vectors and the use of the same for gene therapy Abandoned AU2003273983A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10248141.5 2002-10-11
DE10248141A DE10248141B4 (de) 2002-10-11 2002-10-11 Nukleinsäuren und deren Verwendung für die Gentherapie
PCT/EP2003/011252 WO2004035799A2 (de) 2002-10-11 2003-10-10 Virale vektoren und deren verwendung für die gentherapie

Publications (2)

Publication Number Publication Date
AU2003273983A1 true AU2003273983A1 (en) 2004-05-04
AU2003273983A8 AU2003273983A8 (en) 2004-05-04

Family

ID=32102775

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003273983A Abandoned AU2003273983A1 (en) 2002-10-11 2003-10-10 Viral vectors and the use of the same for gene therapy

Country Status (11)

Country Link
US (1) US8067227B2 (enExample)
EP (1) EP1556411B1 (enExample)
JP (2) JP4615311B2 (enExample)
AU (1) AU2003273983A1 (enExample)
CY (1) CY1114777T1 (enExample)
DE (1) DE10248141B4 (enExample)
DK (1) DK1556411T3 (enExample)
ES (1) ES2440951T3 (enExample)
PT (1) PT1556411E (enExample)
SI (1) SI1556411T1 (enExample)
WO (1) WO2004035799A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069272A2 (en) * 2003-02-05 2004-08-19 Movecare Ltd Adjuvant combination for use in the immunization of a mamal comprising il2 and il12
DE102005055128B4 (de) * 2005-11-15 2015-04-02 Universität Rostock Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
CN102174479B (zh) * 2011-03-02 2013-04-03 北京锤特生物科技有限公司 靶向性治疗人肿瘤的溶肿瘤腺病毒及其应用
US11951157B2 (en) 2011-10-11 2024-04-09 Universitat Zurich Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
PL3351261T3 (pl) 2011-10-11 2021-12-06 Universität Zürich Lek złożony zawierający IL-12 i środek do blokowania cząsteczek hamujących komórki T w terapii nowotworów
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
SG10201913163PA (en) 2015-12-18 2020-03-30 Oncosec Medical Inc Plasmid constructs for heterologous protein expression and methods of use
EP3211000B1 (en) * 2016-02-25 2019-01-30 Provecs Medical GmbH Novel immunostimulating vector system
PL3458083T3 (pl) 2016-05-18 2023-03-13 Modernatx, Inc. Polinukleotydy kodujące interleukinę-12 (il12) i ich zastosowania
KR20240144261A (ko) 2017-02-28 2024-10-02 사노피 치료적 rna
EP3628010A4 (en) 2017-05-02 2021-02-17 Nektar Therapeutics IMMUNOTHERAPEUTIC TUMOR TREATMENT PROCEDURE
AU2019208892B2 (en) * 2018-01-19 2022-02-03 Kolon Life Science, Inc. Recombinant vaccinia virus and pharmaceutical composition comprising same
KR102907902B1 (ko) 2018-08-01 2026-01-02 난트퀘스트, 인크. 면역 요법의 안정한 유전적 변형을 위한 귀소 수용체 또는 사이토카인, 및 키메라 항원 수용체를 포함하는 4 시스트론 시스템
US11230699B2 (en) * 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5573764A (en) * 1994-01-21 1996-11-12 Genetics Institute, Inc. Use of interleukin-12 to prevent graft versus host disease
WO2000041508A2 (en) 1999-01-15 2000-07-20 Mount Sinai School Of Medicine Of The City University Of New York Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines
KR20020010206A (ko) * 2000-07-27 2002-02-04 이시우 인터루킨 12와 보조활성인자 ｂ7.1 유전자를 함유하는ｄｎａ 벡터 및 이벡터가 도입된 항암 세포백신
WO2002027007A2 (en) * 2000-09-25 2002-04-04 Regents Of The University Of Michigan Production of viral vectors

Also Published As

Publication number Publication date
CY1114777T1 (el) 2016-12-14
EP1556411A2 (de) 2005-07-27
DE10248141A1 (de) 2004-09-02
WO2004035799A2 (de) 2004-04-29
JP4615311B2 (ja) 2011-01-19
SI1556411T1 (sl) 2014-01-31
AU2003273983A8 (en) 2004-05-04
WO2004035799A3 (de) 2004-06-10
JP2006511212A (ja) 2006-04-06
US20060153805A1 (en) 2006-07-13
DE10248141B4 (de) 2007-04-19
DK1556411T3 (da) 2014-01-20
JP2011036251A (ja) 2011-02-24
ES2440951T3 (es) 2014-01-31
US8067227B2 (en) 2011-11-29
PT1556411E (pt) 2014-01-07
EP1556411B1 (de) 2013-10-02

Similar Documents

Publication Publication Date Title
AU2003210497A1 (en) Gene delivery system and methods of use
AU2003209226A1 (en) Adiponectin gene therapy
AU2002305151A1 (en) Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en) Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002336288A1 (en) Weed controller metabolism proteins, genes thereof and use of the same
AU2002303261A1 (en) Gene brcc2 and diagnostic and therapeutic uses thereof
AU2003273983A8 (en) Viral vectors and the use of the same for gene therapy
AU2003277910A1 (en) Ocular gene therapy
AU2003274905A1 (en) Recombinant double-stranded rna phage, and use of the same
AU2002347813A1 (en) Chimeric viral vectors for gene therapy
AU2003263036A1 (en) SPAN-Xb GENE AND PROTEIN FOR THE DIAGNOSIS AND TREATMENT OF CANCER
AU2003256280A1 (en) Methods of delivering gene therapy agents
AU2002319460A1 (en) Improvement of gene expression in vectors
AU2002302247A1 (en) Genes and proteins involved in the biosynthesis of enediyne ring structures
AU2002303262A1 (en) Gene shinc-1 and diagnostic and therapeutic uses thereof
AU2002257585A1 (en) Nucleic acids of the human abca12 gene, vectors containing such nucleic acids, and uses thereof
AU2003269257A1 (en) Use of cap-1 for the therapy of asthma
AU2003256931A1 (en) USES OF CIRCADIAN GENE mPER2
AU2002316788A1 (en) Retroviral vectors for gene therapy
AU2003259689A1 (en) 3-imino-2-indolones for the treatment of depression and/or anxiety
AU2002953516A0 (en) Genetic therapy and genetic modification
AU2003222262A1 (en) Arrestin gene, polypeptide and methods of use thereof
AU2003267475A1 (en) Tumor targeting agents and uses thereof
AU2002238761A1 (en) Avidin-pseudotyped viral vectors and their use
AU2002240094A1 (en) Anti-apoptopic gene scc-s2 and diagnostic and therapeutic uses thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase